|Bid||0.0350 x N/A|
|Ask||0.0416 x N/A|
|Day's Range||0.0408 - 0.0408|
|52 Week Range||0.0408 - 0.0759|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for AWY.MULearn more
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
World first study utilizing Somalogic SomaScan® assay# to assess up to 7,000 plasma proteins in Long COVID-19 patients has elucidated novel blood markers as potential diagnostic and therapeutic targetsProvisional patent applications have been filed in the United States (US) to seek protection for these new inventionsA potential therapeutic marker known to be modulated by ATL1102 in DMD patients has been identified as suggestive of its therapeutic potential as a treatment for Long COVID-19Collabo
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Figure 1 Quad RNA ddPCR (Pooled) Figure 2 Quad RNA ddPCR (Female) LGMDR2, also referred to as dysferlinopathy, is a rare genetic muscle disease caused by mutations in the dysferlin gene (DYSF)Animal study conducted at MCRI in collaboration with Jain Foundation in the USStudy results showed significant decreases in target CD49d RNA and key immune cell RNA levels in the muscleData supports progression into a longer-term efficacy study planned for 3Q/4Q2022 Mark Diamond, Antisense Therapeutics Mana